Compare Toronto-Dominion Bank (TD) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toronto-Dominion Bank vs TransMedics Group Inc — how do they compare? Toronto-Dominion Bank trades at $114.39 (market cap $185.79B), while TransMedics Group Inc trades at $77.47 (market cap $2.74B). The key difference: Toronto-Dominion Bank is far larger — about 67.8× TransMedics Group Inc's market cap, and Toronto-Dominion Bank pays a 2.84% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Toronto-Dominion Bank for 84 Days and TransMedics Group Inc for 24 Days on average.
| TD | TMDX | |
|---|---|---|
Market Cap | $185.79B | $2.74B |
Volume | 3,263,867 | 949,331 |
Sector | Financials | Health |
52-Week High | $124.80 | $150.42 |
52-Week Low | $78.32 | $61.99 |
Typical Hold Time | 84 Days | 24 Days |
Enterprise Value | $559.06B | $3.13B |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TD Bank trades at $114.39, up 0.46% with bearish technical signals despite strong earnings beats. The stock shows robust fundamentals with 24.88% net margin and 13.64% ROE, supported by a $10 billion buyback program announced September 2026. Revenue growth accelerated to $61.28 billion in 2025 with profit margins recovering to 33.51%. Analyst consensus leans bullish with 9 buy ratings versus 8 holds and no sell recommendations.
TD presents a compelling value opportunity with reasonable P/E of 17.36 and consistent earnings outperformance. Key risks include declining operating cash flow trends and elevated debt-to-asset ratio of 20.86%. The bank's $108 billion Canadian infrastructure commitment and U.S. branch expansion provide growth catalysts, though technical indicators suggest near-term pressure.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
